Selective PFKFB4 Inhibitor Compounds for Cancer Glycolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective PFKFB4 inhibitors that can disrupt the kinase domain of PFKFB4 in cancer cells to decrease glucose metabolism and growth without affecting PFKFB1 and PFKFB3, while ensuring good oral bioavailability and avoiding toxicity.
Innovation Solution
Development of specific compounds that selectively inhibit PFKFB4 by targeting its kinase domain, reducing glycolytic flux, and treating cancer by administering effective amounts of compounds such as 5-[(8-methoxyquinolin-4-yl)amino]pentyl nitrate (5MPN) and 5-[(8-methoxyl-methylquinolin-1-ium-4-yl)amino]pentyl nitrate (MPN-2), which reduce fructose-2,6-bisphosphate (F2,6BP) and cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PFKFB4 inhibitors are developed to selectively target PFKFB4, then glycolytic flux and cell proliferation are reduced, but selectivity against PFKFB1, PFKFB2, and PFKFB3 must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups positioned at particular locations in the molecular structure to interact with unique features of the PFKFB4 kinase domain. The compounds contain a quinoline or quinolinium core with specific substituents (R1-R6 groups) that are positioned to form selective interactions with amino acid residues in the PFKFB4 active site, particularly targeting the hinge region and hydrophobic pockets that are distinct from other PFKFB isozymes.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as the nature of substituent groups (R1-R6), their positions, and the core structure (quinoline vs. quinolinium) to optimize selectivity for PFKFB4. The compounds explore different charge states (neutral vs. cationic quinolinium), different chain lengths, and various functional groups to fine-tune the interaction with PFKFB4 while avoiding off-target effects on other isozymes.
2Reliability
If PFKFB4 inhibitors are administered to treat cancer, then tumor growth is suppressed, but oral bioavailability must be sufficient for effective treatment
Solution Approach 1:
The patent applies parameter changes by modifying physicochemical parameters of the compounds, including molecular weight, lipophilicity, and charge state, to optimize oral bioavailability. The quinolinium cationic form (MPN-2) was specifically designed to improve membrane permeability and absorption. The compounds were optimized to have appropriate logP values and molecular properties that facilitate oral absorption while maintaining PFKFB4 inhibitory activity.
Solution Approach 2:
The patent employs prodrug strategies where the active compound is administered in a modified form that is more stable and absorbable orally, then converted to the active form in vivo. This approach allows the compound to survive gastrointestinal conditions and achieve sufficient plasma concentrations, effectively using a 'disposable' prodrug form that converts to the therapeutic agent.
3Productivity
If PFKFB4 inhibitors are used to reduce glucose metabolism in cancer cells, then cell proliferation is decreased, but toxicity to normal cells must be avoided
Solution Approach 1:
The patent applies local quality by exploiting the differential expression and functional importance of PFKFB4 in cancer versus normal cells. The compounds are designed to selectively inhibit PFKFB4, which is overexpressed and critically important for glycolysis in cancer cells, while having minimal effect on PFKFB4 in normal tissues. This selective inhibition spares normal cells that rely less on PFKFB4-mediated glycolysis.
Solution Approach 2:
The patent employs partial action by achieving sufficient inhibition of PFKFB4 in cancer cells to suppress tumor growth without completely eliminating all PFKFB4 activity in the body. The compounds are designed to achieve therapeutic efficacy at concentrations that selectively affect cancer cells while maintaining adequate PFKFB4 function in normal physiology, avoiding excessive inhibition that would cause toxicity.
Data Source
AI summary
Methods and pharmaceutical compositions for inhibiting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) and the treatment of cancer are described.